376 related articles for article (PubMed ID: 26872697)
1. Interleukin-35 Limits Anti-Tumor Immunity.
Turnis ME; Sawant DV; Szymczak-Workman AL; Andrews LP; Delgoffe GM; Yano H; Beres AJ; Vogel P; Workman CJ; Vignali DA
Immunity; 2016 Feb; 44(2):316-29. PubMed ID: 26872697
[TBL] [Abstract][Full Text] [Related]
2. Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Li Y; Wang Z; Lin H; Wang L; Chen X; Liu Q; Zuo Q; Hu J; Wang H; Guo J; Xie L; Tang J; Li Z; Hu L; Xu L; Zhou X; Ye L; Huang Q; Xu L
Front Immunol; 2020; 11():806. PubMed ID: 32477338
[TBL] [Abstract][Full Text] [Related]
3. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion.
Zhang Y; Eliav Y; Shin SU; Schreiber TH; Podack ER; Tadmor T; Rosenblatt JD
Cancer Immunol Immunother; 2013 Jan; 62(1):87-99. PubMed ID: 22772949
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity.
Simon AK; Jones E; Richards H; Wright K; Betts G; Godkin A; Screaton G; Gallimore A
Eur J Immunol; 2007 Mar; 37(3):758-67. PubMed ID: 17294404
[TBL] [Abstract][Full Text] [Related]
5. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
[TBL] [Abstract][Full Text] [Related]
6. Serine enrichment in tumors promotes regulatory T cell accumulation through sphinganine-mediated regulation of c-Fos.
Ma S; Sandhoff R; Luo X; Shang F; Shi Q; Li Z; Wu J; Ming Y; Schwarz F; Madi A; Weisshaar N; Mieg A; Hering M; Zettl F; Yan X; Mohr K; Ten Bosch N; Li Z; Poschet G; Rodewald HR; Papavasiliou N; Wang X; Gao P; Cui G
Sci Immunol; 2024 Apr; 9(94):eadg8817. PubMed ID: 38640251
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ Drives T
Overacre-Delgoffe AE; Chikina M; Dadey RE; Yano H; Brunazzi EA; Shayan G; Horne W; Moskovitz JM; Kolls JK; Sander C; Shuai Y; Normolle DP; Kirkwood JM; Ferris RL; Delgoffe GM; Bruno TC; Workman CJ; Vignali DAA
Cell; 2017 Jun; 169(6):1130-1141.e11. PubMed ID: 28552348
[TBL] [Abstract][Full Text] [Related]
8. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.
Zhang Q; Chikina M; Szymczak-Workman AL; Horne W; Kolls JK; Vignali KM; Normolle D; Bettini M; Workman CJ; Vignali DAA
Sci Immunol; 2017 Mar; 2(9):. PubMed ID: 28783703
[TBL] [Abstract][Full Text] [Related]
9. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
Kawalekar OU; O'Connor RS; Fraietta JA; Guo L; McGettigan SE; Posey AD; Patel PR; Guedan S; Scholler J; Keith B; Snyder NW; Blair IA; Milone MC; June CH
Immunity; 2016 Feb; 44(2):380-90. PubMed ID: 26885860
[TBL] [Abstract][Full Text] [Related]
10. LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP; Marciscano AE; Drake CG; Vignali DA
Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.
Scharping NE; Menk AV; Moreci RS; Whetstone RD; Dadey RE; Watkins SC; Ferris RL; Delgoffe GM
Immunity; 2016 Aug; 45(2):374-88. PubMed ID: 27496732
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.
Schietinger A; Philip M; Krisnawan VE; Chiu EY; Delrow JJ; Basom RS; Lauer P; Brockstedt DG; Knoblaugh SE; Hämmerling GJ; Schell TD; Garbi N; Greenberg PD
Immunity; 2016 Aug; 45(2):389-401. PubMed ID: 27521269
[TBL] [Abstract][Full Text] [Related]
13. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Koyama S; Akbay EA; Li YY; Herter-Sprie GS; Buczkowski KA; Richards WG; Gandhi L; Redig AJ; Rodig SJ; Asahina H; Jones RE; Kulkarni MM; Kuraguchi M; Palakurthi S; Fecci PE; Johnson BE; Janne PA; Engelman JA; Gangadharan SP; Costa DB; Freeman GJ; Bueno R; Hodi FS; Dranoff G; Wong KK; Hammerman PS
Nat Commun; 2016 Feb; 7():10501. PubMed ID: 26883990
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
Pfirschke C; Engblom C; Rickelt S; Cortez-Retamozo V; Garris C; Pucci F; Yamazaki T; Poirier-Colame V; Newton A; Redouane Y; Lin YJ; Wojtkiewicz G; Iwamoto Y; Mino-Kenudson M; Huynh TG; Hynes RO; Freeman GJ; Kroemer G; Zitvogel L; Weissleder R; Pittet MJ
Immunity; 2016 Feb; 44(2):343-54. PubMed ID: 26872698
[TBL] [Abstract][Full Text] [Related]
15. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.
Zhang Q; Vignali DA
Immunity; 2016 May; 44(5):1034-51. PubMed ID: 27192568
[TBL] [Abstract][Full Text] [Related]
16. CD4+CD25+ regulatory T cells in tumor immunity.
Chen X; Du Y; Lin X; Qian Y; Zhou T; Huang Z
Int Immunopharmacol; 2016 May; 34():244-249. PubMed ID: 26994448
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors: a patent review (2010-2015).
Collin M
Expert Opin Ther Pat; 2016 May; 26(5):555-64. PubMed ID: 27054314
[TBL] [Abstract][Full Text] [Related]
18. The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements.
Procaccini C; Carbone F; Di Silvestre D; Brambilla F; De Rosa V; Galgani M; Faicchia D; Marone G; Tramontano D; Corona M; Alviggi C; Porcellini A; La Cava A; Mauri P; Matarese G
Immunity; 2016 Feb; 44(2):406-21. PubMed ID: 26885861
[TBL] [Abstract][Full Text] [Related]
19. Expanding antigen-specific regulatory networks to treat autoimmunity.
Clemente-Casares X; Blanco J; Ambalavanan P; Yamanouchi J; Singha S; Fandos C; Tsai S; Wang J; Garabatos N; Izquierdo C; Agrawal S; Keough MB; Yong VW; James E; Moore A; Yang Y; Stratmann T; Serra P; Santamaria P
Nature; 2016 Feb; 530(7591):434-40. PubMed ID: 26886799
[TBL] [Abstract][Full Text] [Related]
20. CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Delconte RB; Kolesnik TB; Dagley LF; Rautela J; Shi W; Putz EM; Stannard K; Zhang JG; Teh C; Firth M; Ushiki T; Andoniou CE; Degli-Esposti MA; Sharp PP; Sanvitale CE; Infusini G; Liau NP; Linossi EM; Burns CJ; Carotta S; Gray DH; Seillet C; Hutchinson DS; Belz GT; Webb AI; Alexander WS; Li SS; Bullock AN; Babon JJ; Smyth MJ; Nicholson SE; Huntington ND
Nat Immunol; 2016 Jul; 17(7):816-24. PubMed ID: 27213690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
